Trump replaced architect James McCrery with Washington-based Shalom Baranes Associates to lead the $300-million White House ballroom project, demoting McCrery to consultant. The new ballroom will span ...

Apple’s Vice President of Human Interface design, Alan Dye, is leaving the company to lead a new studio within Meta’s Reality Labs division. The move appears to be aimed at raising the bar on the user ...

TL;DR: Apple faces a significant C-suite exodus with four top executives departing, including AI chief John Giannandrea and UI design head Alan Dye, now joining Meta. This unprecedented talent loss ...

It was a bustling bonanza for the preview of Design Miami 2025 yesterday. With over 70 presenters, the theme was “Make Believe,” and yes, there was a lot of inventive wares for homes of varying styles ...

We documented the toxic fallout of a green technology. By Peter S. Goodman, Will Fitzgibbon and Samuel Granados Visuals by Finbarr O’Reilly and Carmen Abd Ali Promotional videos from the Association ...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The ...

Great AI doesn’t happen in isolation. These UX strategies — from confidence scores to graceful error recovery — turn users into active collaborators. The AI ...

Johan Andersson's team at Paradox used to lean on the practice more, but Andersson said he "doesn't believe" in it these days. When you purchase through links on our site, we may earn an affiliate ...

Read this application story to discover how completely dry-running lead screw assemblies were used in the thumb of a prosthetic hand design. This grease-free solution provides a precise and powerful ...

Some protein powders and shakes contain unsafe levels of lead, according to a Consumer Reports investigation. In the report, published Tuesday, Consumer Reports analyzed 23 protein powders and shakes ...

Phase IIb data of Metsera Inc.’s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.’s ...

Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents This study reviewed all industry-sponsored phase I clinical trial protocols ...